Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.

ABSTRACT:

Purpose

Glioblastoma (GBM) carries a dismal prognosis despite standard multimodal treatment with surgery, chemotherapy and radiation. Immune checkpoint inhibitors, such as PD1 blockade, for treatment of GBM failed to show clinical benefit. Rational combination strategies to overcome resistance of GBM to checkpoint monotherapy are needed to extend the promise of immunotherapy to GBM management. Emerging evidence suggests that protein phosphatase 2A (PP2A) plays a critical role in the signal transduction pathways of both adaptive and innate immune cells and that inhibition of PP2A could enhance cancer immunity. We investigated the use of a PP2A inhibitor, LB-100, to enhance antitumor efficacy of PD1 blockade in a syngeneic glioma model.

Methods

C57BL/6 mice were implanted with

SUBMITTER: Maggio D 

PROVIDER: S-EPMC7467059 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature